McKesson Corporation $MCK Stake Boosted by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its position in McKesson Corporation (NYSE:MCK) by 15.6% in the third quarter, HoldingsChannel reports. The firm owned 271,391 shares of the company’s stock after buying an additional 36,636 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in McKesson were worth $231,716,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MCK. Nvwm LLC grew its holdings in shares of McKesson by 933.3% in the third quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 28 shares in the last quarter. Delos Wealth Advisors LLC bought a new stake in McKesson during the second quarter worth $27,000. Trellis Wealth Advisors LLC bought a new stake in McKesson during the third quarter worth $32,000. GK Wealth Management LLC bought a new stake in McKesson during the third quarter worth $38,000. Finally, Clearstead Trust LLC purchased a new position in McKesson in the second quarter worth $37,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insider Activity at McKesson

In other McKesson news, EVP Francisco Fraga sold 800 shares of the firm’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $995.80, for a total value of $796,640.00. Following the completion of the transaction, the executive vice president directly owned 5,423 shares of the company’s stock, valued at $5,400,223.40. This trade represents a 12.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the transaction, the chief accounting officer owned 521 shares of the company’s stock, valued at $464,445.45. This trade represents a 17.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,212 shares of company stock valued at $1,164,182. Corporate insiders own 0.06% of the company’s stock.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: UBS raised its price target to $1,200, implying additional upside and reinforcing the bullish view on McKesson’s pharmaceutical distribution and healthcare-services businesses. UBS raises target for McKesson stock
• Positive Sentiment: Leerink raised its target from $1,030 to $1,070, adding to a series of upward revisions from analysts. Leerink raises McKesson price target
• Positive Sentiment: McKesson recently reported quarterly earnings and revenue above consensus estimates. EPS was $9.93 versus $9.56 expected, while revenue reached $105.38 billion, up 7.7% year over year. Management’s fiscal 2027 EPS guidance of $44.20–$45.00 also supports the growth narrative. McKesson outperforms broader market
• Neutral Sentiment: Mizuho lifted its price target from $905 to $1,020 but maintained a “neutral” rating. The revised target is close to, but below, the current market valuation, suggesting limited near-term upside in that analyst’s view. Mizuho adjusts McKesson price target
• Negative Sentiment: Executive Vice President Francisco Fraga sold 800 shares worth approximately $796,640. However, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its significance as a discretionary bearish signal. McKesson executive stock sale

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MCK. Leerink Partners upped their price objective on McKesson from $1,030.00 to $1,070.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Barclays lifted their target price on McKesson from $925.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 19th. Bank of America boosted their price target on shares of McKesson from $950.00 to $1,050.00 in a report on Thursday, August 6th. Mizuho increased their price target on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, Wall Street Zen upgraded shares of McKesson from a “hold” rating to a “buy” rating in a report on Saturday. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $997.12.

McKesson Trading Up 1.9%

McKesson stock opened at $1,029.52 on Wednesday. The firm has a 50 day simple moving average of $902.90 and a 200 day simple moving average of $839.47. McKesson Corporation has a 1-year low of $723.68 and a 1-year high of $1,030.27. The firm has a market capitalization of $120.03 billion, a price-to-earnings ratio of 27.55, a P/E/G ratio of 2.01 and a beta of 0.30.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.56 by $0.37. The firm had revenue of $105.38 billion for the quarter, compared to the consensus estimate of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The business’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, equities research analysts forecast that McKesson Corporation will post 44.71 EPS for the current year.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.